STAAR Surgical Company

NasdaqGM:STAA Stock Report

Market Cap: US$1.2b

STAAR Surgical Valuation

Is STAA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of STAA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: STAA ($24.82) is trading below our estimate of fair value ($59.31)

Significantly Below Fair Value: STAA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for STAA?

Key metric: As STAA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for STAA. This is calculated by dividing STAA's market cap by their current earnings.
What is STAA's PE Ratio?
PE Ratio56.1x
EarningsUS$21.78m
Market CapUS$1.22b

Price to Earnings Ratio vs Peers

How does STAA's PE Ratio compare to its peers?

The above table shows the PE ratio for STAA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.5x
VIVO Meridian Bioscience
35.2xn/aUS$1.5b
EMBC Embecta
15x27.0%US$1.2b
UFPT UFP Technologies
35.8x16.8%US$1.9b
AVNS Avanos Medical
32xn/aUS$694.0m
STAA STAAR Surgical
56.1x33.7%US$1.2b

Price-To-Earnings vs Peers: STAA is expensive based on its Price-To-Earnings Ratio (56.1x) compared to the peer average (27.6x).

Price to Earnings Ratio vs Industry

How does STAA's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
0.9xn/aUS$8.08m
PAVM PAVmed
0.4x-90.0%US$6.39m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
No more companies available in this PE range
STAA 56.1xIndustry Avg. 35.2xNo. of Companies9PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: STAA is expensive based on its Price-To-Earnings Ratio (56.1x) compared to the US Medical Equipment industry average (35.2x).

Price to Earnings Ratio vs Fair Ratio

What is STAA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

STAA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio56.1x
Fair PE Ratio42x

Price-To-Earnings vs Fair Ratio: STAA is expensive based on its Price-To-Earnings Ratio (56.1x) compared to the estimated Fair Price-To-Earnings Ratio (42x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst STAA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$24.82
US$41.89
+68.8%
25.5%US$60.00US$23.00n/a11
Dec ’25US$29.10
US$42.98
+47.7%
23.1%US$60.00US$27.00n/a11
Nov ’25US$28.56
US$44.47
+55.7%
21.6%US$60.00US$27.00n/a10
Oct ’25US$35.88
US$49.54
+38.1%
15.9%US$60.00US$37.00n/a10
Sep ’25US$33.09
US$50.49
+52.6%
16.0%US$60.00US$37.00n/a11
Aug ’25US$39.95
US$51.22
+28.2%
14.9%US$60.00US$37.00n/a11
Jul ’25US$47.42
US$51.68
+9.0%
13.1%US$60.00US$40.00n/a10
Jun ’25US$41.53
US$52.31
+26.0%
13.1%US$60.00US$40.00n/a9
May ’25US$44.69
US$49.17
+10.0%
19.5%US$60.00US$33.00n/a9
Apr ’25US$39.04
US$43.72
+12.0%
17.6%US$53.00US$32.00n/a9
Mar ’25US$33.31
US$40.88
+22.7%
21.3%US$53.00US$30.00n/a8
Feb ’25US$28.70
US$42.25
+47.2%
20.8%US$53.00US$30.00n/a8
Jan ’25US$31.21
US$45.11
+44.5%
19.5%US$56.00US$33.00n/a9
Dec ’24US$32.99
US$47.75
+44.7%
16.6%US$56.00US$35.00US$29.108
Nov ’24US$43.32
US$51.71
+19.4%
16.6%US$64.00US$40.00US$28.567
Oct ’24US$40.18
US$53.25
+32.5%
17.1%US$65.00US$40.00US$35.888
Sep ’24US$43.06
US$56.56
+31.3%
12.4%US$66.00US$45.00US$33.099
Aug ’24US$52.80
US$71.78
+35.9%
11.6%US$84.00US$55.00US$39.959
Jul ’24US$52.57
US$76.00
+44.6%
12.7%US$85.00US$55.00US$47.429
Jun ’24US$57.78
US$78.78
+36.3%
13.0%US$95.00US$60.00US$41.539
May ’24US$72.82
US$77.56
+6.5%
11.9%US$90.00US$60.00US$44.699
Apr ’24US$63.95
US$79.50
+24.3%
10.8%US$90.00US$60.00US$39.048
Mar ’24US$56.69
US$79.50
+40.2%
10.8%US$90.00US$60.00US$33.318
Feb ’24US$72.96
US$80.33
+10.1%
14.9%US$105.00US$60.00US$28.709
Jan ’24US$48.54
US$80.22
+65.3%
14.9%US$105.00US$60.00US$31.219
Dec ’23US$59.13
US$85.50
+44.6%
9.7%US$105.00US$78.00US$32.998

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 04:00
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/27
Annual Earnings2023/12/29

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

STAAR Surgical Company is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joanne WuenschBMO Capital Markets U.S. (Historical)
Michael GormanBTIG
John YoungCanaccord Genuity